Clinical Trials
19 trialsNCT00113113 2024-08-02
Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction
Astex Pharmaceuticals, Inc.
Phase 1 Completed
NCT00113256 2024-08-02
Orathecin + Gemcitabine Versus Placebo + Gemcitabine in Chemonaive Non-Resectable Pancreatic Cancer
Astex Pharmaceuticals, Inc.
Phase 2/3 Terminated
NCT00005869 2013-12-04
Nitrocamptothecin Compared With Gemcitabine in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00005870 2013-12-04
Nitrocamptothecin Compared With Other Chemotherapy in Treating Patients With Recurrent or Refractory Cancer of the Pancreas
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00005871 2013-12-04
Nitrocamptothecin or Fluorouracil in Treating Patients With Recurrent or Refractory Pancreatic Cancer
National Cancer Institute (NCI)
Phase 3 Unknown
NCT00005872 2013-12-04
Nitrocamptothecin in Treating Patients With Recurrent Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00005873 2013-12-04
Nitrocamptothecin in Treating Patients With Locally Recurrent or Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00005874 2013-12-04
Nitrocamptothecin in Treating Patients With Soft Tissue Sarcomas
National Cancer Institute (NCI)
Phase 2 Completed
NCT00005875 2013-12-04
Nitrocamptothecin in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00005876 2013-12-04
Nitrocamptothecin in Treating Patients With Locally Advanced or Metastatic Stomach Cancer That Cannot Be Removed During Surgery
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00005877 2013-12-04
Nitrocamptothecin in Treating Patients With Advanced or Recurrent Colorectal Cancer
National Cancer Institute (NCI)
Phase 2 Unknown
NCT00006267 2013-07-09
Nitrocamptothecin in Treating Patients With Recurrent or Metastatic Ovarian Epithelial or Primary Peritoneal Cancer
GOG Foundation
Phase 2 Withdrawn
NCT00006047 2012-09-26
Combination Therapy With Oral 9-Nitrocamptothecin & Oral Etoposide
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT00005826 2012-09-24
Nitrocamptothecin in Treating Patients With Glioblastoma Multiforme
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00006026 2012-09-24
Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00006082 2012-09-24
Nitrocamptothecin in Treating Patients With Advanced Small Cell Lung Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00006230 2012-09-24
Nitrocamptothecin in Treating Patients With Advanced Ovarian Cancer
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00492141 2012-08-02
Aerosol L9-NC and Temozolomide in Ewing's Sarcoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00249990 2010-01-07
Phase II Study of Aerosolized Liposomal 9-Nitro-20 (S)- Camptothecin (L9NC)
University of New Mexico
Phase 2 Completed